hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06375720 id: FujianUTCM-2 briefTitle: Efficacy of Different Doses of Tai Chi Chuan on Cognitive Function in Persons With Mild Cognitive Impairment overallStatus: NOT_YET_RECRUITING date: 2024-05-05 date: 2025-06-15 date: 2025-12-15 date: 2024-04-19 date: 2024-04-19 name: Lidian Chen class: OTHER name: Peking University Third Hospital briefSummary: To determine the relationship between the effects of different frequencies and duration of Tai Chi Chuan in dose parameters to improve cognitive function in elderly persons with mild cognitive impairment. conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 350 type: ESTIMATED name: Lower frequency, shorter period of Tai Chi Chuan name: Higher frequency, shorter period of Tai Chi Chuan name: Lower frequency, longer period of Tai Chi Chuan name: Higher frequency, longer period of Tai Chi Chuan name: Standard Health Education measure: Montreal Cognitive Assessment measure: Montreal Cognitive Assessment measure: Wechsler Memory Scale measure: Digit Symbol Substitution Test measure: Trial Making Test part B measure: Stroop Color Word Test measure: Boston Naming Test measure: Rey-Osterrieth Complex Graphics Test measure: Rey Auditory Verbal Learning Test measure: The Pittsburgh Sleep Quality Index (PSQI) measure: 12-Item Short Form Health Survey measure: Blood glucose metabolism index measure: Blood lipid metabolism index measure: functional Magnetic Resonance Imaging measure: Electroencephalogram measure: Heart rate variability measure: Gut microflora sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375707 id: HERO-KC23 briefTitle: Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer overallStatus: RECRUITING date: 2024-01-09 date: 2025-11 date: 2025-12 date: 2024-04-19 date: 2024-04-19 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER name: Zhejiang Cancer Hospital briefSummary: Evaluate the efficacy and safety of Ribociclib in combination with NSAI versus physician's choice of chemotherapy sequential endocrine therapy in HR+/HER2- advanced breast cancer. conditions: Advanced Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 144 type: ESTIMATED name: physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS name: Ribociclib combined with NSAI±OFS measure: Progression Free Survival measure: Progression Free Survival2 measure: Time to treatment failure measure: Overall response rate (ORR) measure: Overall survival(OS) measure: Time To Response (TTR) measure: Clinical benefit rate(CBR) measure: Change from baseline in the global health status/QOL scale score by using FACT-B questionnaire measure: Frequency/severity of adverse events, lab abnormalities sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jiangsu Provincial People's Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210000 country: China name: Wei Li, Ph.D role: CONTACT phone: 025-68306360 email: real.lw@163.com name: Wei Li, Ph.D role: PRINCIPAL_INVESTIGATOR lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06375694 id: IRB00025485 briefTitle: Probiotic Effect on Dietary Nitrate to Plasma Nitrite Production ( OPEDNPN ) acronym: OPEDNPN overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-05 date: 2025-05 date: 2024-04-19 date: 2024-04-19 name: Wake Forest University class: OTHER name: University of South Florida briefSummary: Nitric Oxide (NO) is an important molecule that is produced naturally in the body and that helps maintain healthy blood flow. Low availability of NO contributes to many diseases while administration of NO is therapeutic.
In addition to being made naturally in the body, NO can be obtained through the diet via the Nitrate-Nitrite-NO cycle. Nitrate, which is abundant in green leafy vegetables and beetroot juice, is partially converted to nitrite by oral bacteria. The nitrate and nitrite are taken up into the blood and nitrite is converted into NO. Remaining nitrate in the blood is taken back up into the mouth by salivary glands and the cycle continues. Emerging studies suggest that the Nitrate-Nitrite-NO cycle may contribute to cardiovascular health. In addition, there have been many studies where dietary nitrate is given to increase NO and treat various conditions.
In laboratory experiments, certain bacterial species have been shown to block nitrate to nitrite conversion by other oral bacteria. These nitrite depleting species are found in a commercially available oral probiotic designed to improve oral health. The purpose of this study is to examine if use of the probiotic negatively affects the Nitrate-Nitrite-NO cycle. Nitrate to Nitrite conversion will be assessed by measuring plasma levels of nitrite before and after consumption of nitrate-rich beetroot juice. Dietary nitrate to plasma nitrite conversion will assessed at baseline and after one week of consumption of the probiotic or a placebo (follow-up). The primary hypothesis of this study is that participants that consume the probiotic will have lower nitrate to nitrite conversion at follow-up compared to baseline and that there will be no significant change in nitrate to nitrite conversion between baseline and follow-up for participants who consume the placebo.
While this study does not aim to treat any specific disease, it is intended to elucidate a basic physiological function that may be relevant to cardiovascular health and certain NO-based therapeutics. conditions: Hypertension conditions: Cardiovascular Diseases conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized into two groups with one group receiving the oral probiotic and the other receiving the placebo. Each group will take their intervention 2X a day for 7 days. primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Participants will not know which group they are in. The lozenges will be distributed in unmarked bottles whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: Herbiotics Oral + Ent Probiotic measure: Dietary Nitrate Conversion to Plasma Nitrite measure: Percentage Lactobaciluus sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375681 id: 2019-1378: R01 id: 1R01AG076157-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01AG076157-01 id: A487400 type: OTHER domain: UW Madison briefTitle: Effectiveness of Cognitive Training in Older and Younger Adults overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-01 date: 2028-01 date: 2024-04-19 date: 2024-04-19 name: University of Wisconsin, Madison class: OTHER name: National Institute on Aging (NIA) briefSummary: The proposed study will enroll 1600 participants to examine the effectiveness of cognitive training. Participants will be randomized into different experimental groups and can expect to participate for up to 15 hours of research over 4 to 8 weeks. conditions: Cognitive Change studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: Following Pre-testing, participants randomly assigned into the full study will be further randomly assigned to a total of 9 unique experimental conditions for the full 2x2x2+1 factorial design.
nctId: NCT06375668 id: CT/NB/140/2020/PR-MS briefTitle: The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women overallStatus: ACTIVE_NOT_RECRUITING date: 2022-03-15 date: 2024-01-15 date: 2024-06-15 date: 2024-04-19 date: 2024-04-24 name: Nordic Biotic Sp. z o.o. class: INDUSTRY briefSummary: Osteoporosis is a systemic condition characterized by low bone mass and altered bone tissue microarchitecture, with the resulting greater bone fragility leading to fractures. Osteoporosis develops as a result of genetic and environmental factors, with the patient's lifestyle playing an important role. Recent years saw an emergence of reports on the significance of the intestinal microbiota in the development of osteoporosis, thus new ways of modifying the composition and activity of microbiota have been sought, and the potential role of probiotics has been considered. Probiotics are defined as live microorganisms, which-when administered at appropriate doses-are beneficial to the host's health. Probiotics both modify the gut microbiota composition and directly affect the human body. Recently published clinical studies demonstrated that probiotics may facilitate osteoporosis treatment and prevention. The current randomized double-blind placebo-controlled study will assess the effect of a dietary intervention via oral supplementation of Lactobacillus plantarum and Lactobacillus paracasei in a population of Polish postmenopausal women on their bone mineral density assessed via bone densitometry-derived T-scores of the lumbar segment of the spine (L1-L4). Study subjects will take the provided probiotic formulation/placebo orally once daily for 12 months. conditions: Osteoporosis, Postmenopausal conditions: Bone Density, Low studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 170 type: ACTUAL name: Probiotic name: Placebo measure: The effect of intervention on bone mineral density measure: Changes in the level of calcium measure: Changes in the level of phosphorus measure: Changes in the level of alkaline phosphatase measure: Changes in the level of vitamin D measure: Changes in the level of C-reactive protein measure: Changes in Body Mass Index (BMI) measure: Changes in type of stools measure: Changes in the number of bowel movements measure: Changes in severity of abdominal pain measure: Changes in severity of bloating measure: Occurrence of adverse events measure: Satisfaction with the intervention sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Private Specialist Practice city: Bytom zip: 41-902 country: Poland lat: 50.34802 lon: 18.93282 facility: Specialist Practice city: Katowice zip: 40-750 country: Poland lat: 50.25841 lon: 19.02754 facility: Clinical Research Center city: Poznań zip: 60-773 country: Poland lat: 52.40692 lon: 16.92993 hasResults: False
nctId: NCT06375655 id: STUDY20240085 briefTitle: Texting to Promote Breastfeeding (TOPS) overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2025-07-31 date: 2025-07-31 date: 2024-04-19 date: 2024-04-24 name: Lydia Furman class: OTHER briefSummary: The purpose of the study is to see if a program of text messages that support and promote breastfeeding for expecting and delivered African-American/Black women (called TEAM2BF), as compared to a national maternal health texting program (called Text4baby), can result in more women being able to breastfeed their infant. Because breastfeeding is healthy for mothers and babies, and because fewer African-American/Black women decide to breastfeed and continue breastfeeding than many other racial and ethnic groups, researchers like us are trying to figure out ways to be supportive to African-American/Black mothers who might be interested in breastfeeding. The investigators will enroll up to 80 mothers and their infants at UHCMC. conditions: Increased Breastfeeding studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 80 type: ESTIMATED name: Team2BF name: Text4baby measure: Percentage of participants who do not opt out of receipt of text messages measure: Percentage of participants who said texts were helpful as measured by questionnaire measure: Percentage of participants who would refer a friend/family to the texting program measure: Percentage of participants who are exclusively breastfeeding at 2 months postpartum as measured by participant report/chart review measure: Percentage of participants who are exclusively breastfeeding as measured by participant report/chart review measure: Percentage of participants who are partially breastfeeding as measured by participant report/chart review sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ahuja Rainbow Center for Women and Children city: Cleveland state: Ohio zip: 44103 country: United States name: Lydia Furman, MD role: CONTACT phone: 216-675-6691 email: lydia.furman@uhhospitals.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06375642 id: SHR1316-HMPL012-HAIC-01 briefTitle: A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2025-08-31 date: 2026-08-31 date: 2024-04-19 date: 2024-04-19 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: Southeast Asia and China have the highest incidence of intrahepatic cholangiocarcinoma worldwide, with limited treatment options and large unmet medical needs.
Hepatic arterial infusion chemotherapy (HAIC) has gradually emerged as a promising treatment option for patients with hepatocellular carcinoma (HCC). Increasing evidence suggests that infusion of HAIC, which maintains high local concentrations of toxic agents in tumors without embolism, provides a significant survival benefit for patients with advanced HCC and is well-tolerated. However, there is limited evidence for the efficacy of HAIC for intrahepatic cholangiocarcinoma.
Irinotecan liposome (nal-IRI) is a concentrate of an infusion solution containing 5 mg/ml irinotecan trihydrate (irinotecan sucrose salt) active substance, which is encapsulated in liposomes and prevents premature conversion of the drug to SN-38 in the liver. Liposomal irinotecan prolongs the circulation time of the drug in the plasma of patients and prolongs the tumor exposure of the drug compared to conventional irinotecan.Nal-IRI based protocol has shown positive results in the phase III trial of pancreatic carcinoma.
Adebrelima(SHR-1316) is a recombinant humanized IgG4 antibody that binds efficiently and specifically to human and cynomolgus programmed cell death ligand 1 (PD-L1, CD274, or B7-H1), a cell surface molecule that plays an important role in T cell immune function, and stimulates IFN-γ secretion from mixed lymphocyte reactions (MLRs) of dendritic cells (DCs) and CD4 + T cells.
This study aims to evaluate the efficacy and safety of irinotecan liposome-based hepatic arterial infusion chemotherapy combined with adebrelimab and surufatinib in the treatment of intrahepatic cholangiocarcinoma, which may bring significant clinical benefit to the iCC patients with new treatment options. conditions: Intrahepatic Cholangiocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Adebrelimab measure: Objective Response Rate measure: Disease Control Rate measure: Overall Survival measure: Progress-Free Survival measure: Incidence and severity of AE and SAE measure: Dose suspension rate caused by adverse events measure: dose termination rate caused by adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Cancer Hospital Airport Hospital city: Tianjin state: Tianjin zip: 300308 country: China lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06375629 id: EDAP TMS briefTitle: ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate Cancer acronym: ES-HIFU overallStatus: RECRUITING date: 2023-04-20 date: 2027-04-20 date: 2027-04-20 date: 2024-04-19 date: 2024-04-19 name: EDAP TMS S.A. class: INDUSTRY briefSummary: The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device. conditions: Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: FocalOne measure: Evaluation of adverse events measure: Evaluation of quality of life measure: Evaluation of urinary incontinence measure: Erectile function assessment measure: Urinary Symptoms sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitario Puerta del Mar status: RECRUITING city: Cadiz zip: 21 11009 country: Spain name: Cristina Salvatierra Pérez, Doctor role: CONTACT phone: +34 956 00 21 00 email: cris_salvatierra86@hotmail.com lat: 36.52672 lon: -6.2891 facility: Hospital General Universitario Gregorio Marañón C/ Doctor Esquerdo status: RECRUITING city: Madrid zip: 46 28007 country: Spain name: Carlos Hernández Fernández, Doctor role: CONTACT phone: +34 912 05 38 54 email: carlos.hernandez@salud.madrid.org lat: 40.4165 lon: -3.70256 facility: Hospital Universitario Central De Asturias status: RECRUITING city: Oviedo zip: 33011 country: Spain name: Jorge Garcia Rodriguez, Doctor role: CONTACT phone: +34 985 10 80 00 email: garciajorge70@gmail.com lat: 43.36029 lon: -5.84476 facility: Hospital Universitario Marqués De Valdecilla status: RECRUITING city: Santander zip: 39008 country: Spain name: Mario Dominguez Esteban role: CONTACT phone: +34 942 42 06 26 email: mariodominguezesteban@gmail.com lat: 43.46472 lon: -3.80444 facility: Hospital Consorcio General Universitario de Valencia status: RECRUITING city: Valencia zip: 46014 country: Spain name: Emilio Mr López Alcina, Doctor role: CONTACT phone: +34 960 64 00 78 email: e.lopezalcina@gmail.com lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06375616 id: KY2024-023 briefTitle: Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-04 date: 2024-04-19 date: 2024-04-19 name: Shen Lei class: OTHER briefSummary: The goal of this clinical trial is to compare the safety and efficacy of nafamostat mesylate (NM) and unfractionated heparin (UFH) in the process of renal replacement therapy (RRT) for patients suffering from sepsis associated acute kidney injury (SA-AKI). The main questions it aims to answer are:
Participants will receive NM or UFH as anticoagulation during RRT for a minimum of 7 days. Bleeding symptoms, platelet count and coagulation function will be monitored daily. Platelet changes during the 7-day treatment period and survival status at 28 days post-treatment will be recorded. conditions: Sepsis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 156 type: ESTIMATED name: Nafamostat Mesylate name: Unfractionated Heparin measure: Platelet decline rate measure: Satisfaction of filter anticoagulation measure: All-cause mortality at 28 days sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huashan Hospital, Fudan University city: Shanghai state: Shanghai country: China name: Lei Shen, MD role: CONTACT phone: 86-021-52887920 email: sh_leisen@126.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06375603 id: SMARTALPHA-NERVEBLOX-1001 briefTitle: Nerve and Plane Block Data Collection Study for the Development of Artificial Intelligence-assisted Software overallStatus: COMPLETED date: 2022-12-01 date: 2023-05-01 date: 2023-05-01 date: 2024-04-19 date: 2024-04-19 name: Smart Alfa Teknoloji San. ve Tic. A.S. class: INDUSTRY name: Ankara University briefSummary: The primary objective of this observational study is to acquire ultrasound images (raw data) from nerve and plane block regions to develop artificial intelligence-guided nerve block software (Nerveblox). The study aims to acquire raw ultrasound video from 200 volunteers' planned nerve and plane block regions. These participants will undergo ultrasound scans administered by expert clinicians proficient in these techniques in their clinical practice. The data collection devices utilized in this study are FDA-cleared general-purpose ultrasound devices. conditions: Ultrasound Imaging of Anatomical Structures conditions: Nerve Block studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ACTUAL name: Ultrasound scans measure: Assessment of image quality sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara University School of Medicine city: Ankara zip: 06230 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06375590 id: 2024-NavIIcusp briefTitle: NavIIcusp: Bicuspid Aortic Valve Stenosis With Navitor Platform International Experience overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-05-01 date: 2024-04-19 date: 2024-04-19 name: Didier TCHETCHE class: OTHER name: Abbott briefSummary: The aim of this prospective registry is to evaluate the clinical impact of the new Navitor prosthesis (Abbott, Minneapolis, MN, USA) in BAV and evaluate both the main sizing methods (the classical annular or the supra-annular with ICD measurement at 4 mm above the virtual basal ring). conditions: Bicuspid Aortic Valve studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Transcatheter Aortic Valve Implantation measure: 30-day device success (Rate) measure: 1 year at least moderate bioprosthetic valve deterioration measure: 1 year severe patient-prosthesis mismatch measure: 30 days and 1 year all-cause and cardiovascular mortality measure: 30 days and 1 year stroke sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique Pasteur city: Toulouse state: Occitanie zip: 31076 country: France name: Didier Tchétché, MD role: CONTACT name: Didier Tchétché role: PRINCIPAL_INVESTIGATOR name: Chiara De Biase, MD, PhD role: SUB_INVESTIGATOR lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06375577 id: LMS-24-Dean-1 briefTitle: Speed of Absorption overallStatus: RECRUITING date: 2024-06 date: 2025-04 date: 2025-04 date: 2024-04-19 date: 2024-04-22 name: Lancaster University class: OTHER briefSummary: The purpose of this study is to look at how fast commercially available supplements containing carbohydrate can get into the bloodstream. If carbohydrate, in the form of glucose, gets into the blood faster, this can provide an instant energy source and help fuel the body during exercise. We will be testing three supplements, namely Voom Pocket Rocket, SIS Go Isotonic Energy Gel, and Maurten Gel 160. Each participant will complete all three conditions, consuming one of each supplement at random per condition. The study requires participation from male runners, cyclists and triathletes who are aged between 18-35.
All participants will undergo the same measures - blood sampling for blood glucose, blood lactate, and insulin, and monitoring of gas exchange during each study visit. primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: Both the participants and investigators will be blinded to what supplement they are consuming on each visit. Each supplement will taste the same, and be placed into identical packaging, and be randomly labelled (e.g., A, B, C). This will be done to avoid potential bias. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 16 type: ESTIMATED name: 45 grams Voom Pocket Rocket Electro Energy name: 45 grams SIS Go Isotonic Energy Gel name: 45 grams Maurten Gel 160 measure: Blood Glucose measure: Blood Lactate measure: Insulin measure: Gas Exchange sex: MALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Lancaster University status: RECRUITING city: Lancaster state: Lancashire zip: LA1 4AT country: United Kingdom lat: 54.04649 lon: -2.79988 hasResults: False